Oxybutynin topical gel in the treatment of overactive bladder

G Willy Davila
Department of Gynecology, Cleveland Clinic Florida, Weston, Florida, USA

Abstract: Overactive bladder (OAB), often accompanied by urinary incontinence, is most prevalent among the elderly, but also affects many middle-aged men and women in the US. OAB may severely impair quality of life, and its overall economic costs to society are substantial. Although antimuscarinic agents relieve OAB symptoms effectively, treatment persistence generally is low. This has been attributed in part to the occurrence of dry mouth and other anticholinergic adverse events. High plasma concentrations of N-desethyloxybutynin (DEO), an active metabolite of oxybutynin, have been identified as the major cause of anticholinergic adverse effects associated with oral oxybutynin. Transdermal formulations of oxybutynin generate much lower DEO plasma concentrations compared with oral formulations. In a placebo-controlled US Phase III study in patients with OAB, the recently approved oxybutynin topical gel (OTG) was efficacious and well tolerated. Dry mouth occurred in 6.9% of patients treated with OTG and 2.8% of patients on placebo. Incidences of other anticholinergic events were low and similar for OTG and placebo. OTG rarely caused application site skin reactions. OTG provides significant benefits to patients with OAB, particularly those who are sensitive to anticholinergic adverse effects.

Keywords: overactive bladder, oxybutynin topical gel, antimuscarinic, urinary urgency, incontinence

Introduction

Overactive bladder (OAB) is a syndrome characterized by urinary urgency with or without incontinence and is usually accompanied by urinary frequency and nocturia. Results of the National Overactive BLadder Evaluation (NOBLE) program suggest that the prevalence of OAB in the US is similar for men (16%) and women (16.9%), but OAB with urge incontinence affects significantly more women (7.6%) than men (2.6%). The prevalence of OAB increases with age in an essentially linear association from 25 to 75 years. OAB with urge incontinence in women was shown to increase sharply during middle age; as a result, approximately 12% of women aged 45–54 years are affected. A population-based survey conducted in Canada and 4 European countries estimated the overall prevalence of OAB at 11.8%.

OAB can severely impair physical and mental well-being. Nocturia reduces quality of sleep, and OAB symptoms, particularly if accompanied by incontinence, may reduce work productivity and sexual activity, and limit mobility and social interactions. Results from several studies suggest that OAB with incontinence significantly increases the incidence and severity of depression. Incontinence has been associated with recurrent urinary tract infections in women and increased risk of falls and consequent
fractures in elderly women. The costs of treating OAB-related urinary infections and injuries from falls in the US were estimated at $2 billion in 2000. Total costs during the same year for diagnosis and treatment of OAB, consequent care, and lost productivity were estimated at $12 billion.

Bladder filling status and micturition reflex are controlled by the parasympathetic nervous system. The cause of idiopathic OAB symptoms remains essentially unknown, and muscarinic acetylcholine receptor antagonists remain the only pharmacotherapy with a clinically proven mechanism for treating OAB. It is generally believed that antimuscarinics ameliorate the symptoms of OAB by promoting bladder detrusor muscle relaxation during the storage phase as a result of M3 receptor antagonism. However, on the basis of animal studies, it has been suggested recently that antimuscarinics also modulate bladder afferent information, including urge sensation, from the bladder to the central nervous system through several mechanisms.

**Evolution of oxybutynin in treatment of OAB**

Oxybutynin is a well established treatment for OAB and has been commercially available in the US since the 1970s. It is one of a growing number of antimuscarinic agents that have received a Grade A recommendation from the International Consultation on Incontinence for the treatment of OAB. Results of a recent meta-analysis of clinical studies of currently licensed antimuscarinics found no statistically significant differences in efficacy among these agents and no statistically significant association between antimuscarinic therapy and serious adverse events. However, antimuscarinics varied regarding their adverse effect profiles and effects on health-related quality of life (HRQoL). Anticholinergic adverse effects, particularly dry mouth, are common in patients receiving oral antimuscarinics and are a likely cause of low treatment persistence.

Over the years, a number of formulations of oxybutynin have been developed, including various oral formulations and 2 transdermal formulations. The originally developed immediate-release oral formulation is associated with a high incidence of dry mouth and other anticholinergic adverse effects. Introduction of the extended-release oral formulation of oxybutynin significantly reduced the incidence of anticholinergic events and consequently improved medication adherence compared with immediate-release oral oxybutynin. However, the extended-release formulation is still associated with a relatively high incidence of dry mouth, which has exceeded 50% in some clinical studies. Pharmacokinetic evidence suggests that the anticholinergic adverse effects of oral oxybutynin are largely attributable to high plasma concentrations of N-desethyl oxybutynin (N-DEO), an active metabolite of oxybutynin. N-DEO is generated in large quantities in the liver and gut by first-pass metabolism of orally administered oxybutynin involving cytochrome P-450 (CYP-450). The plasma concentrations of N-DEO generated from immediate-release oxybutynin may be up to 10 times those of oxybutynin itself. The improved anticholinergic adverse event profile of extended-release oxybutynin compared with immediate-release oxybutynin is attributable to a reduction in the ratio of total N-DEO to oxybutynin plasma exposures. For the extended-release formulation, steady-state plasma exposure of N-DEO is approximately four times that of oxybutynin. N-DEO and oxybutynin appear to have similar affinities for muscarinic M3 receptors, which represent the dominant receptor subtype in the salivary gland, and are believed to mediate bladder smooth muscle contraction during micturition.

To avoid the first-pass hepatic and gastrointestinal metabolism of orally administered oxybutynin, transdermal formulations of oxybutynin have been developed. The first transdermal formulation (oxybutynin transdermal delivery system [TDS]) was a patch delivery system. In pharmacokinetic studies involving healthy volunteers, single-dose and steady-state plasma concentrations of N-DEO obtained with oxybutynin TDS were substantially lower than those obtained with oral formulations. The mean ratio of N-DEO to oxybutynin steady-state plasma exposures observed with oxybutynin TDS was 1.2 or 1.3, depending on the study. Moreover, healthy subjects produced significantly more saliva if they received transdermal rather than extended-release oxybutynin. Subsequent Phase II and Phase III clinical studies in mostly female patients with OAB demonstrated that the efficacy of oxybutynin TDS is similar to that of immediate-release oxybutynin and extended-release tolterodine. In one of these studies, the incidence of dry mouth associated with oxybutynin TDS was similar to that associated with placebo. The excellent anticholinergic tolerability of oxybutynin TDS was also evident in a six-month, community-based, open-label study of almost 3000 patients, of whom only 2.6% experienced dry mouth. Consistent with this observation, oxybutynin TDS was found to improve HRQoL significantly.

A drawback of oxybutynin TDS compared with oral formulations appears to be the propensity of the patch delivery system to cause application site skin reactions in some patients. In the community-based, open-label study...
of oxybutynin TDS, 14% of the mostly female patients reported application site reactions, including pruritus, erythema, and dermatitis. Application site pruritus also has been observed in patients using placebo patches (6.1% in a placebo-controlled Phase III study). This raises questions concerning the precise cause of oxybutynin TDS–associated application site reactions. Skin occlusion and desquamation caused by the patch may be important contributing factors, suggesting that the incidence of application site reactions could be substantially reduced by using a different TDS. Following this rationale, a new gel-based TDS for oxybutynin has been developed. Oxybutynin topical gel (OTG) was specifically designed to improve the skin tolerability of transdermal delivery while maintaining its excellent anticholinergic tolerability profile. OTG was approved by the US Food and Drug Administration in January 2009.

**Oxybutynin topical gel**

**Formulation and pharmacokinetics**

One dose of OTG consists of 1 g of a semisolid and colorless gel that contains oxybutynin 100 mg (10% w/w) and has a volume of less than a quarter of a tablespoon (1.14 mL). Each dose of OTG is packaged in a single sachet and should be applied once daily to the abdomen, upper arm/shoulder, or thigh. The application site location has only minor effects on the steady-state pharmacokinetics of OTG and therefore is not expected to have a clinically meaningful impact on the efficacy or tolerability of OTG. OTG is fragrance-free and not expected to have a clinically meaningful impact on the pharmacokinetics of OTG and therefore is specifically designed to improve the skin tolerability of transdermal delivery while maintaining its excellent anticholinergic tolerability profile. OTG was approved by the US Food and Drug Administration in January 2009.

![Structural formula of oxybutynin](image)

**Figure 1** Structural formula of oxybutynin.

Optimal skin tolerability and effective drug absorption. The OTG formulation does not include a permeation enhancer. To enter the systemic circulation, oxybutynin must penetrate the stratum corneum and epidermis and enter the capillary system located in the dermis. Unpublished pharmacokinetic data suggest that the release of oxybutynin into the systemic circulation occurs gradually. A sufficiently slow release of oxybutynin into the circulation is an essential prerequisite for the once-daily dosing schedule. It has been shown previously that the stratum corneum and the dermis may function as storage depots during the delivery of topically applied steroids to the systemic circulation. It is conceivable that the skin assumes a similar reservoir function during the delivery of topically applied oxybutynin.

During development of the OTG formulation, it was important to find a formulation strength (ie, oxybutynin concentration in the gel) that would make delivery of the drug both efficient and convenient. A 10% (w/w) OTG formulation was found to meet these criteria best.

Comparison of the pharmacokinetic profiles of oxybutynin TDS and OTG in healthy volunteers revealed that both formulations resulted in similar plasma exposures of oxybutynin and N-DEO. After administration of single doses to 20 subjects in a cross-over study, plasma exposures to oxybutynin were 322 ng·h/mL for OTG and 312 ng·h/mL for oxybutynin TDS; the ratio of N-DEO to oxybutynin exposures was 0.8 for OTG and 1.1 for oxybutynin TDS. Mathematical simulations using nonlinear regression models predicted that the two formulations would have very similar steady-state kinetics. This prediction was subsequently borne out by the results of a multiple dosing study in 22 healthy adults. Subjects received 18 daily applications of OTG followed by five applications of oxybutynin TDS every 3.5–4.0 days, or vice versa. The two treatment periods were separated by a 14-day washout period, and the order of treatment was assigned randomly. The 4-day pharmacokinetic profile of oxybutynin was very similar for OTG and oxybutynin TDS (Figure 2). Total plasma exposure to oxybutynin was 322 ng·h/mL for OTG and 312 ng·h/mL for oxybutynin TDS; the ratio of N-DEO to oxybutynin exposure was 0.8 for OTG and 1.1 for oxybutynin TDS (Table 1). The lower ratio for OTG was almost exclusively attributable to a lower plasma exposure to N-DEO for gel versus patch delivery (Table 1, Figure 2).

Because oxybutynin is easily absorbed by the skin, the possibility of transference of oxybutynin to an untreated subject through skin-to-skin contact with a treated patient has been investigated. Healthy couples, each consisting of an untreated and a treated subject, engaged in vigorous
15-minute bare skin contact at the OTG application site one hour after application. Transference appeared to vary widely among couples but was generally small. Exposure due to transference was undetectable in most untreated subjects if the application site was covered with clothing during contact. Given the rigorous but highly artificial experimental conditions of the study, transference under real-life circumstances, if it occurs at all, can be expected to be of little clinical significance. However, for a caregiver who routinely assists a patient in applying OTG, it may be
Oxybutynin gel for overactive bladder

It is advisable to avoid direct skin-to-skin contact with the application site (shortly after application) if the caregiver is sensitive to or contraindicated for anticholinergic agents.

Clinical efficacy

The results of a double-blind, randomized, placebo-controlled Phase III study of OTG in patients with OAB have been published recently.44 The 12-week study was conducted at 76 clinical centers in the US and enrolled a total of 789 patients with urge or mixed urinary incontinence. Most of the patients (89.2%) were women, and slightly more than a third of the study participants were 65 years or older. Approximately a quarter of all patients had previously taken OAB medications. Baseline values indicated that a substantial proportion of patients had severe OAB symptoms. For both treatment groups, the mean number of daily urinary incontinence episodes at baseline was 5.4 and the mean number of daily nocturia events at baseline was 2.5; mean daily frequency at baseline was 12.4 for patients assigned to OTG and 12.2 for those assigned to placebo. Patients receiving OTG experienced a greater reduction in the numbers of daily incontinence episodes (mean decrease −3.0 versus −2.5; \( P < 0.0001 \), Figure 3) and daily frequency episodes (mean decrease −2.7 versus −2.0; \( P = 0.0017 \)) than those receiving placebo, but a significantly greater decrease in nocturia episodes in the OTG group was observed only in patients younger than 65 years (mean decrease −0.91 versus −0.72; \( P = 0.0363 \)). Voided volume at baseline was greater than 160 mL in most patients and on average increased by 21.0 mL in those treated with OTG (placebo 3.8 mL; \( P = 0.0018 \)). At study end, 28% of the patients treated with OTG and 17% of those who received placebo had achieved complete continence.

Efficacy in female patients

The efficacy of OTG specifically in women with OAB was assessed in a subgroup analysis of the Phase III study population.45 Each treatment group included 352 female patients. Mean age was 59 years. Baseline demographic and urinary symptom values for the female subgroup were very similar to those for the total study population. For both treatment groups, the mean number of daily urinary incontinence episodes per day (Figure 3).

### Table 1 Steady-state pharmacokinetics of OTG and OXY-TDS

<table>
<thead>
<tr>
<th>Parameter, mean (SD)</th>
<th>OTG (N = 20)</th>
<th>OXY-TDS (N = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxybutynin AUC[0–96 h], ng/h/mL</td>
<td>321.7 (112.3)</td>
<td>312.5 (67.6)</td>
</tr>
<tr>
<td>N-DEO AUC[0–96 h], ng/h/mL</td>
<td>246.4 (97.0)</td>
<td>338.0 (116.9)</td>
</tr>
<tr>
<td>Ratio, N-DEO/oxybutynin[0–96 h]</td>
<td>0.77 (0.19)</td>
<td>1.07 (0.22)</td>
</tr>
</tbody>
</table>

**Abbreviations:** AUC, area under the plasma concentration-time curve; N-DEO, N-desethyl oxybutynin; OTG, oxybutynin topical gel; OXY-TDS, oxybutynin transdermal system; SD, standard deviation.
patients who received OTG versus placebo experienced significantly greater improvement \((P < 0.0001)\) in daily incontinence episodes (mean decrease \(-3.0\) versus \(-2.5\)), daily frequency (mean decrease \(-2.8\) versus \(-2.0\)), and voided volume (mean increase \(22.7\) mL versus \(4.0\) mL). At study end, 27.0% of women treated with OTG compared with 15.6% of those receiving placebo had achieved complete continence.\(^{45}\)

**Effects on quality of life**

During the Phase III study, HRQoL was evaluated with the five-item Incontinence Impact Questionnaire (IIQ) and the 10-item King’s Health Questionnaire (KHQ). OTG versus placebo was associated with significant improvement in all IIQ domains (ie, emotional health, social relationships, travel, and physical activity; \(P < 0.01\)).\(^{46}\) Moreover, significant HRQoL improvements with OTG versus placebo were observed in the KHQ domains of incontinence impact, symptom severity, role limitations, personal relationships, severity (coping) measures, and sleep/energy \((P < 0.05)\).

**Safety and tolerability**

**Overall tolerability and adverse anticholinergic effects**

No treatment-related serious adverse events were observed during the Phase III study of OTG.\(^{44}\) The overall discontinuation rate because of adverse events was not substantially higher with OTG (4.9%) than with placebo (3.3%, Table 2). The most commonly reported adverse event was dry mouth. The incidence of dry mouth in the OTG group (6.9%) was significantly higher than in the placebo group (2.8%, \(P = 0.0060\), Table 2), but substantially smaller than the incidences of dry mouth reported in comparable studies of oral oxybutynin.\(^{22}\) No treatment-related anticholinergic event other than dry mouth occurred in more than 2% of patients treated with OTG, including constipation (1.3%), dizziness (1.5%), nausea (0.3%), dry eye (0.5%), dysuria (0.3%), and somnolence (0.3%).\(^{44}\) Dry mouth was the only anticholinergic event with a statistically significant difference in incidence between OTG and placebo (Table 2).\(^{44}\)

**Effects on skin**

The skin tolerability of OTG was tested extensively in preclinical and clinical studies. OTG is unlikely to cause phototoxicity because the degree of light absorption by the gel at wavelengths of 290–700 nm is insignificant. A study in albino guinea pigs further suggested that OTG does not elicit dermal reactions or delayed contact sensitization. These findings were confirmed by two dermatologic studies of OTG in healthy subjects. Using the Berger and Bowman scale\(^{47}\) to score cumulative skin irritation in 41 subjects, mean scores obtained with OTG and placebo were 35 and 24, respectively. Both scores were substantially less than 50, which is the lowest score considered as evidence of cumulative irritation. In the second study, 201 subjects received nine OTG applications over a period of 3 weeks and a final challenge application after a rest period of 2 weeks. During the following 72 hours, the frequency and severity of skin reactions were assessed. The vast majority

---

**Table 2** AEs reported during double-blind study treatment

<table>
<thead>
<tr>
<th>No. of patients (%)</th>
<th>OTG ((n = 389))</th>
<th>Placebo ((n = 400))</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1 AE</td>
<td>221 (56.8)</td>
<td>193 (48.3)</td>
<td>0.0160(^\dagger)</td>
</tr>
<tr>
<td>≥1 treatment-related AE</td>
<td>73 (18.8)</td>
<td>45 (11.3)</td>
<td>0.0031(^\dagger)</td>
</tr>
<tr>
<td>≥1 serious AE</td>
<td>7 (1.8)</td>
<td>10 (2.5)</td>
<td>0.4981(^\dagger)</td>
</tr>
<tr>
<td>≥1 treatment-related serious AE</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>AE resulting in study withdrawal</td>
<td>19 (4.9)</td>
<td>13 (3.3)</td>
<td>0.2446(^\dagger)</td>
</tr>
</tbody>
</table>


**Abbreviations:** AE, adverse event; OTG, oxybutynin chloride topical gel.
of subjects receiving OTG (93%) or placebo (94.5%) had no skin reactions.

Excellent skin tolerability of OTG was also observed during the Phase III trial. Application site skin reactions were reported by 5.4% of patients who received OTG and by 1% of those who received placebo. Eight of 389 patients (2.1%) treated with OTG and 3 of 400 patients (0.8%) receiving placebo reported application site pruritus as an adverse event (Table 2). The incidence of application site erythema was similar among patients treated with OTG (1.3% per visit) and those who received placebo (0.9% per visit). At study end, inspection of application sites by the investigator revealed no erythema in 97.4% and 98.7% of patients receiving OTG and placebo, respectively. Among the few patients receiving OTG who had application site erythema, none had severe symptoms, 3 (0.8% of all patients receiving OTG) had moderate symptoms, and 7 (1.8%) had mild symptoms. Three patients (0.8%) in the OTG group and 1 patient (0.3%) in the placebo group discontinued treatment because of application site reactions (reported as adverse events).

Conclusion

OTG is a new transdermal formulation of oxybutynin that was specifically designed to minimize anticholinergic effects and application site skin reactions. Available clinical data show that OTG is efficacious in patients with urge and mixed urinary incontinence and is associated with low incidences of anticholinergic adverse events. OTG appears to have better skin tolerability than oxybutynin TDS, the previously developed transdermal patch formulation of oxybutynin. OTG has rarely caused application site skin reactions, and those that have occurred were mostly mild forms of pruritus and dermatitis. The excellent tolerability of OTG and its efficacy in OAB symptom improvement are most likely responsible for the significant improvements in HRQoL that were seen during treatment. These attributes, together with its convenient once-daily dosing schedule, make OTG a valuable new option for the treatment of OAB.

Acknowledgments

Editorial assistance funded by Watson Pharma Inc was provided by Scientific Connexions, Newtown, Pennsylvania, USA.

Disclosure

The author is a speaker and consultant for Watson Pharmaceuticals.

References


